News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Imperial College Innovations Limited Licenses T Cell Receptor (TCR) Therapy Technology To GANYMED Pharmaceuticals AG


10/19/2005 5:09:21 PM

Transaction valuation potentially £1 million plus royalties on future product sales. Imperial College Innovations Ltd announced today an agreement to license exclusively patents covering the use of T Cell Receptor (TCR) Therapy Technologies and the production of TCRs, developed by Professor Hans Stauss in the Department of Immunology at Imperial College London, to GANYMED Pharmaceuticals AG.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES